KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arbutus Biopharma (ABUS) FCF Margin (2016 - 2025)

Arbutus Biopharma (ABUS) has disclosed FCF Margin for 13 consecutive years, with 445.29% as the latest value for Q4 2025.

  • Quarterly FCF Margin rose 21551.0% to 445.29% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 281.45% through Dec 2025, up 77238.0% year-over-year, with the annual reading at 281.45% for FY2025, 77238.0% up from the prior year.
  • FCF Margin hit 445.29% in Q4 2025 for Arbutus Biopharma, up from 1099.62% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 163.29% in Q1 2022 to a low of 1548.62% in Q3 2024.
  • Historically, FCF Margin has averaged 601.69% across 5 years, with a median of 547.03% in 2021.
  • Biggest five-year swings in FCF Margin: surged 101422bps in 2022 and later tumbled -108026bps in 2024.
  • Year by year, FCF Margin stood at 613.35% in 2021, then skyrocketed by 55bps to 274.2% in 2022, then plummeted by -194bps to 806.15% in 2023, then grew by 18bps to 660.8% in 2024, then soared by 33bps to 445.29% in 2025.
  • Business Quant data shows FCF Margin for ABUS at 445.29% in Q4 2025, 1099.62% in Q3 2025, and 146.65% in Q2 2025.